Literature DB >> 3004704

Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies.

R Taetle, J Castagnola, J Mendelsohn.   

Abstract

In previous studies, an immunoglobulin A, anti-transferrin receptor antibody (42/6) inhibited growth of a variety of normal and malignant human hemopoietic cells. To determine its mechanism of growth inhibition, we compared effects of 42/6 and B3/25, an immunoglobulin G anti-transferrin receptor antibody which does not inhibit lymphocyte growth, on transferrin (TF) binding and uptake. As in previous studies, affinity constants of TF and anti-TF receptor antibodies for human TF receptors at 4 degrees C were similar, but the number of calculated binding sites was higher for the antibodies. Antibody B3/25 did not inhibit TF binding at either 4 degrees C or 37 degrees C. At 4 degrees C, antibody 42/6 inhibited TF binding to normal, mitogen-stimulated mononuclear cells. However, TF did not inhibit 42/6 binding, suggesting 42/6 inhibited TF binding by noncompetitive, possibly steric, mechanisms. When cells were simultaneously exposed to labeled TF and unlabeled anti-TF receptor antibodies at 37 degrees C, 42/6 inhibited TF binding only slightly. Initial uptake of antibodies and TF at 37 degrees C was rapid, but when mononuclear cells or HL60 cells were cultured with either 42/6 or B3/25 for 2 days, TF binding and immunoreactive TF receptor sites decreased. However, TF bound to cells cultured with B3/25 continued to enter the cell, whereas cells cultured with 42/6 would no longer take up bound TF. Studies using HL60 cells grown with soluble iron in lieu of TF showed that changes in TF binding sites and TF uptake were not secondary to growth inhibition. We conclude that incubation with both inhibitory (42/6) and noninhibitory (B3/25) anti-TF receptor antibodies results in decreased TF binding sites. However, exposure to 42/6 also inhibits TF uptake and causes growth inhibition by iron deprivation. Monoclonal antibodies to receptors transporting critical nutrient molecules, such as iron, may inhibit cell growth by blocking ligand access to the cell's interior.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3004704

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor.

Authors:  Patrick P Ng; Gustavo Helguera; Tracy R Daniels; Simon Z Lomas; Jose A Rodriguez; Gary Schiller; Benjamin Bonavida; Sherie L Morrison; Manuel L Penichet
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

2.  Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells.

Authors:  José A Rodríguez; Rosendo Luria-Pérez; Héctor E López-Valdés; David Casero; Tracy R Daniels; Shabnum Patel; David Avila; Richard Leuchter; Sokuntheavy So; Elizabeth Ortiz-Sánchez; Benjamin Bonavida; Otoniel Martínez-Maza; Andrew C Charles; Matteo Pellegrini; Gustavo Helguera; Manuel L Penichet
Journal:  Leuk Lymphoma       Date:  2011-08-28

3.  The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies.

Authors:  Jin Wang; Shaomin Tian; Robby A Petros; Mary E Napier; Joseph M Desimone
Journal:  J Am Chem Soc       Date:  2010-08-18       Impact factor: 15.419

Review 4.  Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.

Authors:  Stephanie Tortorella; Tom C Karagiannis
Journal:  J Membr Biol       Date:  2014-02-27       Impact factor: 1.843

Review 5.  Iron and cancer: more ore to be mined.

Authors:  Suzy V Torti; Frank M Torti
Journal:  Nat Rev Cancer       Date:  2013-04-18       Impact factor: 60.716

Review 6.  Iron in multiple myeloma.

Authors:  Kristina VanderWall; Tracy R Daniels-Wells; Manuel Penichet; Alan Lichtenstein
Journal:  Crit Rev Oncog       Date:  2013

7.  The augmentation of lymphokine-activated killer activity following pulsing of human peripheral blood mononuclear cells with recombinant human interleukin-2.

Authors:  C R Carter; B W Hancock; R C Rees
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  Peptides and growth factors in small cell lung cancer: production, binding sites, and growth effects.

Authors:  G Bepler; M Rotsch; G Jaques; M Haeder; J Heymanns; G Hartogh; P Kiefer; K Havemann
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

9.  1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide.

Authors:  Shasi V Kalivendi; Srigiridhar Kotamraju; Sonya Cunningham; Tiesong Shang; Cecilia J Hillard; B Kalyanaraman
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

10.  Transferrin receptor 1 promotes the fibroblast growth factor receptor-mediated oncogenic potential of diffused-type gastric cancer.

Authors:  Takuya Shirakihara; Hideki Yamaguchi; Tadashi Kondo; Masakazu Yashiro; Ryuichi Sakai
Journal:  Oncogene       Date:  2022-03-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.